 DURHAM, N.C.--BUSINESS WIRE--Aerie Pharmaceuticals, Inc. NASDAQ: AERI, an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the European Commission EC has granted a marketing authorisation for Roclanda netarsudil and latanoprost ophthalmic solution 0.020.005 for the reduction of elevated intraocu 